NCT03875820 2026-03-10
FRAME
Institute of Cancer Research, United Kingdom
Phase 1 Active not recruiting
Clinical Trials
7 trialsNCT04331041 2026-02-17
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT03727880 2026-02-04
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT07126158 2026-01-05
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT05669482 2025-09-02
RAMP205
Verastem, Inc.
Phase 1/2 Active not recruiting
NCT02546531 2021-07-20
Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
Washington University School of Medicine
Phase 1 Completed
NCT02758587 2018-03-19
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
NHS Greater Glasgow and Clyde
Phase 1/2 Unknown